Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Participant & Investigator Blinded, Placebo-Controlled Study to Evaluate the Ability of Intrathecally Administered NIO752 to Lower CSF Total Tau Synthesis in Participants With AD Measured by Stable Isotope Labelling Kinetics

NCT06372821 is registered in ClinicalTrials.gov with University College, London as lead sponsor.

NCT NCT06372821
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06372821 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Participant & Investigator Blinded, Placebo-Controlled Study to Evaluate the Ability of Intrathecally Administered NIO752 to Lower CSF Total Tau Synthesis in Participants With AD Measured by Stable Isotope Labelling Kinetics
Lead sponsor
University College, London
Phase
Phase 1
Overall status
Recruiting
Start date
November 18, 2024
Completion date
July 31, 2026
Enrollment
10 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease, autosomal dominant alzheimer disease due to mutation of amyloid precursor protein (disorder), autosomal dominant alzheimer disease due to mutation of presenilin 1 (disorder), autosomal dominant alzheimer disease due to mutation of presenilin 2 (disorder)